Capecitabine Clinical Trials
180 recruitingDrug
Phase 2111Phase 350Phase 133Not Applicable6Phase 42
Showing 1–20 of 180 trials
Recruiting
Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
Locally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm
National Cancer Institute (NCI)115 enrolled1 locationNCT03907475
Recruiting
Phase 3
A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)
Biliary Tract Cancer
Sichuan Baili Pharmaceutical Co., Ltd.538 enrolled1 locationNCT07582315
Recruiting
Phase 1
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
Gastroesophageal Junction AdenocarcinomaClinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8+10 more
M.D. Anderson Cancer Center24 enrolled1 locationNCT04615013
Recruiting
Phase 3
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
Gastric AdenocarcinomaGastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.570 enrolled1 locationNCT07673887
Recruiting
Phase 2
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
Esophageal Squamous Cell CarcinomaAdvanced Unresectable Gastric AdenocarcinomaAdvanced Gastroesophageal Adenocarcinoma
BeOne Medicines30 enrolled6 locationsNCT07554521
Recruiting
Phase 3
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled195 locationsNCT07060807
Recruiting
Phase 3
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction AdenocarcinomaMetastatic Gastric Adenocarcinoma
BeOne Medicines351 enrolled95 locationsNCT07043400
Recruiting
Phase 2
SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis
Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
Ruijin Hospital60 enrolled2 locationsNCT07384234
Recruiting
Phase 3
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)
Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.446 enrolled1 locationNCT07648914
Recruiting
Phase 2
Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer
Colorectal, Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins66 enrolled1 locationNCT07281768
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC1,530 enrolled305 locationsNCT06393374
Recruiting
Phase 3
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Breast Neoplasms
Merck Sharp & Dohme LLC1,200 enrolled259 locationsNCT06312176
Recruiting
Phase 3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC2,400 enrolled315 locationsNCT06966700
Recruiting
Phase 1Phase 2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Metastatic Breast Cancer
Hoffmann-La Roche1,132 enrolled47 locationsNCT03424005
Recruiting
Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Triple-Negative Breast Cancer
Gilead Sciences1,514 enrolled356 locationsNCT05633654
Recruiting
Phase 1
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
Pancreatic Ductal Adenocarcinoma
Astellas Pharma Global Development, Inc.25 enrolled3 locationsNCT07024615
Recruiting
Phase 1
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Gastric AdenocarcinomaPancreatic AdenocarcinomaGastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.398 enrolled46 locationsNCT05365581
Recruiting
Phase 3
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
Rectal Cancer
Canadian Cancer Trials Group250 enrolled113 locationsNCT06205485
Recruiting
Phase 2
ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases
Liver Metastases
M.D. Anderson Cancer Center120 enrolled1 locationNCT05062317
Recruiting
Phase 2
JS207 a Bispecific Antibody Against PD1-VEGF in Nasopharyngeal Carcinoma
Recurrent/ Metastatic NPC
Chinese University of Hong Kong49 enrolled1 locationNCT07690787